
CLAIMS

1. A compound having Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

X is CH, O, N, or S, wherein R_8 is absent if X is O or S;

Y is O, S, or NR';

R_1, R_2, R_4, R_5, R_6, and R_7 are independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, CO_2R', OCOR', CONR'R", NR"COR', NR'SO_2R", SO_2NR'R", (C=NR')NR"R'", or NR'R"; or

R_7 forms an aryl, cycloalkyl, or heterocyclic group with one of R_5 or R_6;

R_8 is H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, CO_2R', OCOR', CONR'R", SO_2NR'R", or (C=NR')NR"R'";

R_9 represents a 6-chloro and a 5-fluoro group; and


each R', R" and R'" is independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, or heterocyclic; or

R' and R", or R" and R'", form a ring;


R_3 is CONRR', and

R is an optionally substituted cycloalkyl-alkyl or monocyclic-heterocyclic group or a dihydroxyalkyl group not containing a hydroxyl group at the 3-position of the alkyl group.

2. The compound of claim 1, having Formula II or Formula III:




II



III

or a pharmaceutically acceptable salt thereof.


3. The compound of claim 1, having Formula IV:




IV

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 3, having Formula V or Formula VI:




V



VI

or a pharmaceutically acceptable salt thereof.


5. The compound of claim 1, having Formula VII:




VII

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 5, having Formula VIII or Formula IX:



VIII



IX


or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1, wherein one of R_1 and R_2 is optionally substituted aryl or heteroaryl.

8. The compound of claim 1, wherein one of R_1 and R_2 is cycloalkyl, straight or branched alkyl, CONR'R" or CO_2R'.

9. The compound of claim 1, wherein one of R_5 and R_6 is C_{3-18} alkyl, aryl, or heteroaryl.

10. A compound having Formula X:



X

or a pharmaceutically acceptable salt thereof, wherein:

R_1, R_5, and R_7 are independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, CO_2R', OCOR', CONR'R", NR"COR', NR'SO_2R", SO_2NR'R", (C=NR')NR"R'", or NR'R"; or

R_7 forms a heterocyclic group with R_5;

R_9 represents a 6-chloro and a 5-fluoro group; and

each R', R" and R'" is independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, or heterocyclic; or


R' and R", or R" and R'", form a ring;

R_{10} is hydrogen, and

R_{11} is an optionally substituted cycloalkyl-alkyl or monocyclic-heterocyclic group or a dihydroxyalkyl group not containing a hydroxyl group at the 3-position of the alkyl group;


or R_{10} and R_{11} together form an optionally substituted monocyclic-heterocyclic group.

11. The compound of claim 10, having one of Formulae XI-XXVI:




or a pharmaceutically acceptable salt thereof.

12. The compound of claim 11, having Formula XI or Formula XXVI:




XI



XXVI

or a pharmaceutically acceptable salt thereof.


13. The compound of claim 1, having Formula XLVIII:




XLVIII

or a pharmaceutically acceptable salt thereof.


14. The compound of claim 13, having one of Formulae XLIX-LXIV:




XLIX




L




LI




LII




LIII




LIV




LV




LVI




LVII




LVIII




LIX




LX




LXI



LXII




LXIII



LXIV

or a pharmaceutically acceptable salt thereof.

15. A compound having Formula LXV:



LXV

or a pharmaceutically acceptable salt thereof, wherein:

R_1, R_5, and R_4 are independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, CO_2R', OCOR', CONR'R", NR"COR', NR'SO_2R", SO_2NR'R", (C=NR')NR"R'", or NR'R"; or

R_7 forms a heterocyclic group with R_5;

R_9 represents a 6-chloro and a 5-fluoro group; and

each R', R" and R'" is independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, or heterocyclic; or


R' and R", or R" and R'", form a ring;

R_{10} is hydrogen, and


R_{11} is an optionally substituted cycloalkyl-alkyl or monocyclic-heterocyclic group or a dihydroxyalkyl group not containing a hydroxyl group at the 3-position of the alkyl group;

or R_{10} and R_{11} together form an optionally substituted monocyclic-heterocyclic group.

16. The compound of claim 15, having one of Formulae LXVI and LXVII:




LXVI





LXVII


or a pharmaceutically acceptable salt thereof.


17. A compound selected from the group consisting of:





















































and .


18. A compound selected from the group consisting of:






and



19. A compound which is



20. A pharmaceutical composition comprising the compound of any one of claims 1-19 and a pharmaceutically acceptable carrier.

21. An *in vitro* method of inhibiting cell growth and/or division, inducing apoptosis and/or inducing cell cycle arrest in a cell comprising contacting the cell with a compound of any one of claims 1-19.

22. An *in vitro* method of rendering a cell sensitive to additional agent(s) comprising contacting the cell with a compound of any one of claims 1-19.

23. The *in vitro* method of claim 22, further comprising contacting the cell with additional agent(s).

24. The *in vitro* method of claim 23, wherein said additional agent(s) is a chemotherapeutic agent.

25. The *in vitro* method of claim 23, wherein said additional agent(s) is radiation.

26. Use of a compound of any one of claims 1-19 for the preparation of a medicament for treating, ameliorating, or preventing a disorder in an animal.

27. The use of claim 26, wherein the medicament is to be administered to the animal with one further additional agent(s).

28. The use of claim 27, wherein said additional agent(s) is a chemotherapeutic agent.

29. The use of claim 27, wherein said additional agent(s) is radiation.

30. The use of claim 26, wherein said disorder is a hyperproliferative disease.

31. The use of claim 30, wherein said hyperproliferative disease is cancer.

32. The use of claim 27, wherein said medicament is administered prior to said additional agent(s).

33. The use of claim 27, wherein said medicament is administered after said additional agent(s).

34. The use of claim 27, wherein said medicament is administered concurrently with said additional agent(s).

35. An *in vitro* method of inhibiting the interaction between p53 or p53-related proteins and MDM2 or MDM2-related proteins in a cell, comprising exposing the cell to a compound of any one of claims 1-18.

36. An *in vitro* method of inhibiting growth of a hyperproliferative cell containing functional p53 or p53-related proteins, comprising exposing the cell to a compound of any one of claims 1 -19.

37. Use of a compound of any one of claims 1-19 for the preparation of a medicament for treating, ameliorating, or preventing a hyperproliferative disease characterized by expression of functional p53 or p53-related proteins in an animal..

38. An *in vitro* method of rendering a normal cell resistant to chemotherapeutic agents or treatments, comprising contacting the cell with a compound of any one of claims 1 -19.

39. The *in vitro* method of claim 38, wherein said normal cell comprises wild-type p53.

40. Use of a compound of any one of claims 1-19 for the preparation of a medicament for protecting normal cells in an animal with a hyperproliferative disease from the toxic side effects of chemotherapeutic agents or treatments.

41. The use of claim 40, wherein said normal cells comprise wild-type p53.

42. The use of claim 40, wherein said hyperproliferative disease is cancer.

43. The use of claim 42, wherein said cancer comprises a mutation or deletion of p53.

44. Use of a compound of any one of claims 1-19 for the preparation of a medicament for the treatment, amelioration, or prevention of a disorder or condition caused by the administration of a chemotherapeutic agent or treatment.

45. The use of claim 44, wherein said disorder or condition is mucositis, stomatitis, xerostomia, a gastrointestinal disorder, or alopecia.

46. The use of claim 44, wherein the medicament is to be administered to said animal prior to administration of said chemotherapeutic agent or treatment.

47. A kit comprising the compound of any one of claims 1-19.

48. The kit of claim 47, further comprising instructions for administering said compound to an animal.


49. The kit of claim 47, further comprising an additional agent(s).


50. The kit of claim 49, wherein said additional agent(s) is a chemotherapeutic agent.


51. The kit of claim 48, wherein said instructions are for administering said compound to an animal having a hyperproliferative disease.


52. The kit of claim 51, wherein said hyperproliferative disease is cancer.


53. A compound selected from the group consisting of:





















and




54. A compound selected from the group consisting of:








and



.

Claims

1. A compound having Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

X is N;

Y is O, or S;

R_1, R_2, R_4, R_5, R_6, and R_7 are independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, CO_2R', OCOR', CONR'R", NR"COR', NR'SO_2R", SO_2NR'R", (C=NR')NR"R'", or NR'R"; or

R_7 forms an aryl, cycloalkyl, or heterocyclic group with one of R_5 or R_6;


R_8 is H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, CO_2R', OCOR', CONR'R", SO_2NR'R", or (C=NR')NR"R'";

each R', R" and R'" is independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, or heterocyclic; or


R' and R", or R" and R'", form a ring; and

R_3 is $CONHR_{11}$ wherein R_{11} is an optionally substituted cycloalkyl-alkyl or monoheterocycloalkyl-alkyl group or a dihydroxyalkyl group not containing a hydroxyl group at the 3-position of the alkyl group.

2. The compound of claim 1, having Formula II or Formula III:




II



III

or a pharmaceutically acceptable salt thereof.


3. The compound of claim 1, having Formula IV:




IV

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 3, having Formula V or Formula VI:




V



VI

or a pharmaceutically acceptable salt thereof.


5. The compound of claim 1, having Formula VII:




VII

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 5, having Formula VIII or Formula IX:



VIII



IX


or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1, wherein one of R_1 and R_2 is optionally substituted aryl or heteroaryl.

8. The compound of claim 1, wherein one of R_1 and R_2 is cycloalkyl, straight or branched alkyl, amide or ester.

9. The compound of claim 1, wherein one of R_5 and R_6 is $C_{3\text{-}18}$ alkyl, aryl, or heteroaryl.

10. A compound having Formula X:



X

or a pharmaceutically acceptable salt thereof, wherein:

R_{10} is hydrogen, and

R_{11} is an optionally substituted cycloalkyl-alkyl or monoheterocycloalkyl-alkyl group or a dihydroxyalkyl group not containing a hydroxyl group at the 3-position of the alkyl group;

or R_{10} and R_{11} together form an optionally substituted monocyclo-heterocycloalkyl group;

R_1, R_5, and R_7 are independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, CO_2R', OCOR', CONR'R", NR"COR', NR'SO_2R", SO_2NR'R", (C=NR')NR"R'", or NR'R"; or


R_7 forms an aryl, cycloalkyl, or heterocyclic group with one of R_5 or R_6;

R_8 is H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclic, CO_2R', OCOR', CONR'R", SO_2NR'R", or (C=NR')NR"R'"; and


each R', R" and R'" is independently H or optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, or heterocyclic; or

R' and R", or R" and R'", form a ring.


11. The compound of claim 10, having one of Formulae XI-XXVI:




XI




XII




XIII




XIV




XV




XVI




XVII




XVIII




XIX




XX




XXI




XXII




XXIII



XXIV




XXV




XXVI

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 10, having Formula XXVII or Formula XXVIII:




XXVII





XXVIII


or a pharmaceutically acceptable salt thereof.


13. A compound of claim 1 selected from the group consisting of:
































































































































































































































































































































































































































































and .


14. A compound selected from the group consisting of:






































and



or a pharmaceutically acceptable salt thereof.

15. A compound



or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a compound of claims 1, 14, or 15 and a pharmaceutically acceptable carrier.

17. The compound of claims 1, 14, or 15 for use in a method of treating a disorder selected from the group consisting of colon cancer and prostate cancer in an animal, wherein the compound is for administration in a therapeutically effective amount to said animal.

18. The compound of claim 17, wherein said compound is for administering with an additional agent selected from the group consisting of a chemotherapeutic agent and radiation.

19. The compound of claim 18, wherein said compound is for administration prior to said additional agent(s).


20. The compound of claim 18, wherein said compound is for administration after said additional agent(s).


21. The compound of claim 18, wherein said compound is for administration concurrently with said additional agent(s).


22. A kit comprising a compound of claims 1, 14, or 15 and instructions for administering said compound to an animal having cancer, whrerein said cancer is selected from the group consisting of prostate cancer and colon cancer.


23. The kit of claim 22, further comprising a chemotherapeutic agent.


24. A compound selected from the group consisting of:




















and





or a pharmaceutically acceptable salt thereof, or a different pharmaceutically acceptable salt thereof.


25. A compound selected from the group consisting of:










































and



or a pharmaceutically acceptable salt thereof, or a different pharmaceutically acceptable salt thereof.